| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | EVP, Cell &Genetic Therapies
2 companies
Sanna Bastiano serves as an EVP, Cell &Genetic Therapies at VRTX and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 0 buys and 63 sells. Those positions are worth an estimated $15.9M at current prices.
Historically, Sanna Bastiano's trades have earned a below-average insider score of 41/100 across 24 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -24.1%.
The biggest single holding is VRTX (~$15.9M) as EVP, Cell &Genetic Therapies. The recent filings there lean toward selling, a net 35,314 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2021 | VRTX Vertex Pharmaceuticals Inc / Ma | EVP, Cell &Genetic Therapies | Sell | 1,686 | $210.56 | $355,012.33 | -2.1% | +1.0% | +11.1% |